Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Gains from Investment Securities (2019 - 2025)

Maxcyte (MXCT) has disclosed Gains from Investment Securities for 7 consecutive years, with -$155000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 132.22% to -$155000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $349000.0 through Dec 2025, down 98.62% year-over-year, with the annual reading at $2.6 million for FY2025, 81.69% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$155000.0 at Maxcyte, down from $554938.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $24.8 million in Q4 2021, with the low at -$231000.0 in Q4 2023.
  • Average Gains from Investment Securities over 5 years is $2.8 million, with a median of $554938.0 recorded in 2025.
  • The sharpest move saw Gains from Investment Securities skyrocketed 41653.51% in 2021, then tumbled 273.99% in 2023.
  • Over 5 years, Gains from Investment Securities stood at $24.8 million in 2021, then crashed by 99.47% to $132763.0 in 2022, then crashed by 273.99% to -$231000.0 in 2023, then skyrocketed by 308.23% to $481000.0 in 2024, then tumbled by 132.22% to -$155000.0 in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at -$155000.0, $554938.0, and $254000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.